Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romosozumab with high- versus low-intensity exercise in postmenopausal women with low bone density
ACTRN12623000867695Phase 4Recruiting
- Sponsor
- Royal North Shore Hospital
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of romosozumab in osteoporosis and osteopenia (3 arms), sponsored by Royal North Shore Hospital. Primary endpoints: Mean percentage change in lumbar spine bone mineral density and Mean change in five times sit to stand test. Started Apr 2024; status: recruiting.
02
Drugs
romosozumab
03
Conditions
osteoporosisosteopenia
Beyond the preview
Go deeper on ACTRN12623000867695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000867695.